Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Stromal Tumors 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Filgrastim 15Carboplatin 10Ifosfamide 9Doxorubicin 9Cyclophosphamide 9Peripheral Blood Stem Cell Transplantation 7pembrolizumab 6Radiotherapy 6Gemcitabine 6Temozolomide 5Etoposide 5Cisplatin 5Paclitaxel 4Docetaxel 4Amifostine 4aldesleukin 3aflibercept 3Trastuzumab 3Specimen Handling 3Radiosurgery 3Psychiatric Rehabilitation 3Magnetic Resonance Spectroscopy 3Biopsy 3tislelizumab 2sodium thiosulfate 2selinexor 2pazopanib 2palbociclib 2etoposide phosphate 2eribulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × OSI 930 × Gynecologic × Clear all
NCT00603356 2011-09-27

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Astellas Pharma Inc

Phase 1 Completed
60 enrolled
GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Neoplasms, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡